Complement function in mAb-mediated cancer immunotherapy

Trends in Immunology

Volumn 25, Issue 3, 2004, Pages 158-164

  Gelderman, Kyra A ^a   Tomlinson, Stephen ^b   Ross, Gordon D ^c   Gorter, Arko ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA GLUCAN; BEVACIZUMAB; CEAVAC; CETUXIMAB; COMPLEMENT; COMPLEMENT RECEPTOR; COTARA; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MITOMOMAB; MONOCLONAL ANTIBODY; OREGOVOMAB; PEMTUMOMAB; RECOMBINANT ANTIBODY; REGULATOR PROTEIN; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; ZAMYL;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOLYSIS; DIGESTIVE SYSTEM CANCER; DRUG INDICATION; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

EID: 1342345215     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.01.008     Document Type: Review

References (63)

1. Gorter A., Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today. 20:1999;576-582.
2. Ross G.D. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/αMβ2-integrin glycoprotein. Crit. Rev. Immunol. 20:2000;197-222.
3. Vetvicka V. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:1996;50-61.
4. Xia Y. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162:1999;2281-2290.
5. Yan J., et al. β-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163:1999;3045-3052.
6. Hong F. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63:2003;9023-9031.
7. Cheung N.K., et al. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 51:2002;557-564.
8. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129.
9. Trikha M., et al. Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. 13:2002;609-614.
10. Ravetch J.V., Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16:1998;421-432.
11. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:2000;443-446.
12. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 99:2002;754-758.
13. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:2003;3940-3947.
14. Velders M.P., et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. 54:1994;1753-1759.
15. Sliwkowski M.X., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:1999;60-70.
16. Di Gaetano N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171:2003;1581-1587.
17. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2003;. 10.1182/blood-2003-06-2037 ( www.bloodjournal.org/ ).
18. Johnson P., Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30:2003;3-8.
19. Spiridon C.I., et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8:2002;1720-1730.
20. Niehans G.A., et al. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay- accelerating factor), and CD59 (protectin). Am. J. Pathol. 149:1996;129-142.
21. Fishelson Z., et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40:2003;109-123.
22. Cheung N.-K.V., et al. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81:1988;1122-1128.
23. Juhl H., et al. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol. 64:1997;222-230.
24. Gelderman K.A., et al. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32:2002;128-135.
25. Jurianz K., et al. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology. 42:1999;209-218.
26. McDowell J.V., et al. Analysis of the ability of spirochete species associated with relapsing fever, avian borreliosis, and epizootic bovine abortion to bind factor H and cleave c3b. J. Clin. Microbiol. 41:2003;3905-3910.
27. Fedarko N.S., et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 7:2001;4060-4066.
28. Fedarko N.S., et al. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem. 275:2000;16666-16672.
29. Seya T., et al. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies. Leuk. Lymphoma. 12:1994;395-400.
30. Hara T., et al. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br. J. Haematol. 82:1992;368-373.
31. Golay J., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement- mediated cell lysis. Blood. 95:2000;3900-3908.
32. Shin M.L., et al. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J. Immunol. 136:1986;1777-1782.
33. Harris C.L., et al. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology. 100:2000;462-470.
34. Zhang H., et al. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 58:1998;2844-2849.
35. Takizawa H., et al. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152:1994;3032-3038.
36. Caragine T.A., et al. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 62:2002;1110-1115.
37. Yu J., et al. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin. Exp. Immunol. 115:1999;13-18.
38. Chen S.H., et al. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res. 60:2000;3013-3018.
39. Baranyi L., et al. Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology. 82:1994;522-528.
40. Durrant L.G., et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 52:2003;638-642.
41. Blok V.T., et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab. Invest. 80:2000;335-344.
42. Gelderman K.A., et al. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 82:2002;483-493.
43. Golay J., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 98:2001;3383-3389.
44. Bannerji R., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J. Clin. Oncol. 21:2003;1466-1471.
45. Idusogie E.E., et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2001;2571-2575.
46. Ellis J.H., et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155:1995;925-937.
47. Pullyblank A.M., et al. m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer. Br. J. Cancer. 70:1994;753-758.
48. Kroesen B.J., et al. Tumor-targeted immune complex formation: effects on myeloid cell activation and tumor-directed immune cell migration. Int. J. Cancer. 98:2002;857-863.
49. Sokoloff M.H., et al. Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol. Immunother. 49:2000;551-562.
50. + cells by rituximab. Blood. 101:2003;1071-1079.
51. Reiter Y., Fishelson Z. Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J. Immunol. 142:1989;2771-2777.
52. Juhl H., et al. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology. 197:1997;444-459.
53. Juhl H., et al. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab′)2-cobra venom factor conjugate are equally cytotoxic. Mol. Immunol. 27:1990;957-964.
54. Fecke W., et al. Expression of factor I-resistant mutants of the human complement component C3 in heterologous systems. Xenotransplantation. 5:1998;29-34.
55. Blok V.T., et al. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand. J. Immunol. 57:2003;591-599.
56. Andoh A., et al. Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology. 111:1996;911-918.
57. Schmitt C.A., et al. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur. J. Cancer. 35:1999;117-124.
58. Treon S.P., et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 93:1999;1287-1298.
59. Reddy P.K., et al. Interferon-γ upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction. Eur. J. Cancer. 39:2003;397-404.
60. Blok V.T., et al. Bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor- associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J. Immunol. 160:1998;3437-3443.
61. Harris C.L., et al. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin. Exp. Immunol. 107:1997;364-371.
62. Cheung N.K., Modak S. Oral (1→3),(1→4)-β-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 8:2002;1217-1223.
63. + neutrophils and macrophages that produce tumor regression and tumor-free survival. Mol. Immunol. 40:2003;195-196.